Figure 6 indicates that, based on comparisons of expression profiles, the C2 patients are more likely to respond to anti-CTLA-4 and anti-PD-1 immunotherapy. However, the frequent resistance exhibited against immune checkpoint inhibitors indicates that PD-1 or CTLA-4-targeted monotherapy may not fully offset the immunosuppression in the tumor microenvironment (Li X. et al., 2018). This evidence concerns the gene CTLA4 and neoplasm.